Wednesday
11.30 - 12.00

Accelerating change with SGLT2 inhibitors to improve outcomes in T2D

Naresh Kanumilli (UK)
The evidence around cardiorenal disease in Type 2 diabetes
Francesco Giorgino (Italy)
Taking action to reduce cardiorenal morbidity through SGLT2 inhibition
Q&A
Hosted by:
AstraZeneca